Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee. "Typically, we see 3...
网页链接Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee. "Typically, we see 3...
网页链接
精彩评论